臨床外科67巻9号

2012年09月発行

特集 高齢者外科手術における周術期管理 〔老化の影響を知る〕

高齢者に対する薬剤投与の留意点

著者： 西弘二¹ 谷川原祐介¹

所属機関： ¹慶應義塾大学医学部臨床薬剤学

ページ範囲：P.1104 - P.1108

【ポイント】

◆加齢による生理機能変動によって，高齢者の薬物体内動態は若年者と異なる場合が多い．

◆加齢に伴う薬物受容体の発現・活性の変動は薬剤感受性に影響を及ぼす．

◆高齢者への薬剤投与は，加齢に伴う薬物体内動態および感受性変化，さらには多剤併用・合併症を考慮し，適切に用量を減量するなど慎重に行う．

参考文献

1）Klotz U：Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41：67-76, 2009

2）Cusack B, Kelly J, O'Malley K, et al：Digoxin in the elderly：pharmacokinetic consequences of old age. Clin Pharmacol Ther 25：772-776, 1979

3）Yuasa H, Soga N, Kimura Y, et al：Effect of aging on the intestinal transport of hydrophilic drugs in the rat small intestine. Biol Pharm Bull 20：1188-1192, 1997

4）Ramsay SE, Whincup PH, Shaper AG, et al：The relations of body composition and adiposity measures to ill health and physical disability in elderly men. Am J Epidemiol 164：459-469, 2006

5）Beaufrere B, Morio B：Fat and protein redistribution with aging：metabolic considerations. Eur J Clin Nutr 54（Suppl 3）：S48-53, 2000

6）Turnheim K：Drug dosage in the elderly. Is it rational? Drugs Aging 13：357-379, 1998

7）McLean AJ, Le Couteur DG：Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56：163-184, 2004

8）Greenblatt DJ, Allen MD, Harmatz JS, et al：Diazepam disposition determinants. Clin Pharmacol Ther 27：301-312, 1980

9）Wynne HA, Cope LH, Mutch E, et al：The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9：297-301, 1989

10）Durnas C, Loi CM, Cusack BJ：Hepatic drug metabolism and aging. Clin Pharmacokinet 19：359-389, 1990

11）Woodhouse KW, Wynne HA：Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 15：287-294, 1988

12）Butler JM, Begg EJ：Free drug metabolic clearance in elderly people. Clin Pharmacokinet 47：297-321, 2008

13）Le Couteur DG, McLean AJ：The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 34：359-373, 1998

14）Schmucker DL, Woodhouse KW, Wang RK, et al：Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48：365-374, 1990

15）Hunt CM, Westerkam WR, Stave GM：Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44：275-283, 1992

16）Shimada T, Yamazaki H, Mimura M, et al：Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals：studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270：414-423, 1994

17）Hubbard RE, O'Mahony MS, Calver BL, et al：Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol 64：895-900, 2008

18）Parkinson A, Mudra DR, Johnson C, et al：The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199：193-209, 2004

19）Ishizawa Y, Yasui-Furukori N, Takahata T, et al：The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44：1179-1189, 2005

20）Phillips JK, McLean AJ, Hill CE：Receptors involved in nerve-mediated vasoconstriction in small arteries of the rat hepatic mesentery. Br J Pharmacol 124：1403-1412, 1998

21）Andrawis N, Jones DS, Abernethy DR：Aging is associated with endothelial dysfunction in the human forearm vasculature. J Am Geriatr Soc 48：193-198, 2000

22）Lakatta EG, Levy D：Arterial and cardiac aging：major shareholders in cardiovascular disease enterprises：Part I：aging arteries：a“set up”for vascular disease. Circulation 107：139-146, 2003

23）Abernethy DR, Wainer IW, Longstreth JA, et al：Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. J Pharmacol Exp Ther 266：904-911, 1993

24）Abernethy DR：An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol 73：10A-17A, 1994

25）Scarpace PJ：Decreased receptor activation with age. Can it be explained by desensitization? J Am Geriatr Soc 36：1067-1071, 1988

26）Connolly MJ, Crowley JJ, Charan NB, et al：Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 108：401-406, 1995

27）Vestal RE, Wood AJ, Shand DG：Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther 26：181-186, 1979

28）Albrecht S, Ihmsen H, Hering W, et al：The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther 65：630-639, 1999

29）Kanto J, Kangas L, Aaltonen L, et al：Effect of age on the pharmacokinetics and sedative of flunitrazepam. Int J Clin Pharmacol Ther Toxicol 19：400-404, 1981

30）Hernandez-Diaz S, Rodriguez LA：Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation：an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160：2093-2099, 2000

31）Sugiura S, Seki S, Hidaka K, et al：The hemodynamic effects of landiolol, an ultra-short-acting beta1-selective blocker, on endotracheal intubation in patients with and without hypertension. Anesth Analg 104：124-129, 2007

32）Minto CF, Schnider TW, Egan TD, et al：Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 86：10-23, 1997

33）Westmoreland CL, Hoke JF, Sebel PS, et al：Pharmacokinetics of remifentanil（GI87084B）and its major metabolite（GI90291）in patients undergoing elective inpatient surgery. Anesthesiology 79：893-903, 1993

34）Schnider TW, Minto CF, Shafer SL, et al：The influence of age on propofol pharmacodynamics. Anesthesiology 90：1502-1516, 1999

35）Bevan DR, Fiset P, Balendran P, et al：Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anaesth 40：127-132, 1993

36）Baykara N, Solak M, Toker K：Predicting recovery from deep neuromuscular block by rocuronium in the elderly. J Clin Anesth 15：328-333, 2003